A new test to analyze histone protein modifications in DNA.
Official title: HistoneScan™: a multiplex immunoassay for histone epigenetic profiling
Funded at Adeptrix Corporation · NIH-10654855 · Data updated 2026-11-12
This study is testing a new test called HistoneScan™ that can check for different changes in proteins related to gene activity all at once, which could help doctors understand diseases better and create more effective treatments for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Adeptrix Corporation NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | July 1, 2022 |
| Project end | June 30, 2025 |
| Funding year | 2023 |
| Award (this year) | $436,856 |
| NIH project number | 5R44CA272029-02 |
| Project ID | NIH-10654855 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with conditions related to dysregulated gene activity and histone modifications.
✕Less likely to help
Patients without any known genetic or epigenetic disorders may not receive direct benefits from this research.
What this research studies
This research focuses on developing a novel multiplex immunoassay called HistoneScan™ that can detect multiple histone modifications simultaneously. By using advanced techniques such as single bead immunoaffinity capture and mass spectrometry, the assay aims to enhance the detection and quantification of complex histone modifications associated with various diseases. This could provide valuable insights into gene activity regulation and its implications for health. Patients may benefit from improved diagnostic capabilities that could lead to better-targeted therapies.
Why it matters
Potential benefit: If successful, this research could lead to more accurate diagnostics and targeted treatments for diseases linked to histone modifications.
How similar studies have gone: While the approach of multiplex immunoassays is gaining traction, this specific method for histone profiling is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
-
Adeptrix Corporation
Boston, United States Active
Researchers
- Principal investigator: Bergo, Vladislav — Adeptrix Corporation
- Study coordinator: Bergo, Vladislav
Related research
Other NIH-funded projects on the same topics.
-
Measuring activated kinases involved in cancer signaling pathways
This study is working on a new test to help find better combinations of cancer treatments by looking at important proteins involved in cancer growth, so that patients can have more effective options for their care.
-
Developing a test to measure Alzheimer’s disease markers in cerebrospinal fluid
This study is working on a new test that looks at the fluid around your brain and spine to find certain proteins linked to Alzheimer's disease, which could help doctors diagnose it better and personalize treatments just for you.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.